



NEWS RELEASE

FOR IMMEDIATE RELEASE

Contact: Ronald Trahan, APR, President, Ronald Trahan Associates Inc., +1-508-359-4005, x108

STENTYS appoints Michel Darnaud to its Board of Directors

PRINCETON, N.J., and PARIS, Nov. 23, 2010—STENTYS ([STNT.PA](#)), a medical technology company that markets a new generation of innovative stents to treat **Acute Myocardial Infarction (AMI)**, announced today that its board of directors has nominated **Michel Darnaud** as a director.

“Michel Darnaud has immense experience at building and growing international medical device companies, particularly in the interventional cardiology sector. We look forward to his contributions to the STENTYS board, which we believe will be considerable,” said **Jacques Séguin, M.D., Ph.D.**, co-founder and chairman of STENTYS.

Mr. Darnaud is a seasoned executive with 30 years of industry experience in medical technology, including two decades in international senior management positions. Since 2008 he has been president of the **Sorin Group**’s Cardiopulmonary and Intercontinental business, with full global responsibility from R&D to sales. From 2005-2007, Mr. Darnaud was a consultant to executive search firm **Spencer Stuart**, where he established a presence for the firm in the medical technology sector in Europe. From 1998-2005, Mr. Darnaud was president of **Boston Scientific**’s European business, with full P/L responsibility across eight divisions, including interventional cardiology. Additionally, he was chairman of **Eucomed** (European Medical Device Industry Association) in 2004/2005.

Mr. Darnaud will succeed **Brian Kerr** of **Scottish Equity Partners (SEP)**, who has accepted to resign from his position as a director to allow for the co-optation of Mr. Darnaud. The board has accepted to nominate SEP, as represented by Mr. Kerr who wishes to maintain a role at STENTYS, as an observer of the board for at least one year.

STENTYS recently raised **\$31.9 million** (€22.7 million) in an IPO on the NYSE Euronext Paris Stock Exchange; the proceeds are being used to commercialize its innovative stents for treating acute myocardial infarction (AMI) in Europe and to obtain regulatory approval for their commercialization in the U.S.

About STENTYS

Based in Princeton, N.J., and Paris, Stentys has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by **Jacques Séguin, M.D., Ph.D.**, (also founder of **CoreValve**, which was acquired by **Medtronic**) and **Gonzague Issenmann**, Stentys received the CE mark for its flagship products in 2010. Its **self-apposing** stents adapt to the anatomic changes of the arteries in the post-infarction phase and thus prevent the **malapposition** problems associated with conventional stents. Stentys has commenced its marketing activities in several European countries.

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, STENTYS shares. If you wish to obtain further information about STENTYS, please refer to our website www.stentys.com. This press release may contain some forward-looking statements. Although STENTYS considers that these statements are based on reasonable hypotheses at the date of publication of this release, they are by their nature subject to risks and uncertainties which could cause actual results to differ materially from those indicated or projected in these statements. STENTYS operates in a continually changing environment and new risks emerge continually. STENTYS does not undertake and expressly

disclaims any obligation to update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise.

This announcement is not an offer for sale of securities in the United States. The securities referred to herein have not been offered or sold in the United States and may not be offered or sold in the United States of America, except pursuant to a registration statement under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or pursuant to an exemption from registrations thereunder. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.

#####